報價延遲最少15分鐘:2025/05/15 09:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.38/0.75
|
|
企業價值
196.12M
|
| 資產負債 |
|
每股賬面淨值
-0.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
138.10M
|
|
每股收益
1.17
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/15 09:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designedto take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |